Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: hoffy who wrote (24964)	12/9/1998 4:40:00 PM
From: findstock	Respond to of 119973

Why would NBC not name the company a MAJOR breakthrough and that wouldn't mention the company?.....there would be thousands of people calling to find out what the name of the company was that it could impact....

To: hoffy who wrote (24964)	12/9/1998 4:40:00 PM
From: QKAnd	Respond to of 119973

Except gern ran hard the last 15 minutes to close at a high. Holding 8k ans a little worried. Glad I was able to get in from 3.5 and out at 6. Thanks again for the initial posts Greg and NASDBull.

To: hoffy who wrote (24964)	12/9/1998 4:44:00 PM
From: NASDBULL	Read Replies (2) \| Respond to of 119973

ASTM will do VERY well tomorrow!!!! The big difference between GERN and ASTM is that GERN's ownership in the stem cell finding was overlooked in the coverage because of the news focus on John Hopkins University and University of Wisconsin. ASTM will likely get some direct exposure because they are pretty much the only ones involved. Am i correct in assuming this? NASDBULL Read the bold!! Like bone marrow, umbilical cord blood contains the ''mother cells'' that can endlessly produce the cells that the body needs to fight disease, Stiff said. But cord blood cells have the advantage of being ''immunologically naive,'' making them more acceptable to the body and therefore not requiring a perfect donor match that is difficult to find. ''With our ability to expand cord blood cells, not only might most patients have a donor somewhere in the world, but mortality rates may drop significantly -- a real breakthrough,'' Stiff said in a statement released by Loyola. In the process developed by Ann Arbor, Michigan-based Aastrom Biosciences Inc (Nasdaq:ASTM - news)., the cells are placed in a bioreactor -- an apparatus used to grow useful substances from living organisms -- then fed nutrients and put in an incubator.